Connect Biopharma Holdings Ltd (CNTB) - Net Assets
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has net assets worth $55.37 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($67.36 Million) and total liabilities ($11.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Connect Biopharma Holdings Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $55.37 Million |
| % of Total Assets | 82.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.39 |
Connect Biopharma Holdings Ltd - Net Assets Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Also explore CNTB current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual net assets of Connect Biopharma Holdings Ltd from 2018 to 2024. For live valuation and market cap data, see CNTB market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $92.17 Million | -8.79% |
| 2023-12-31 | $101.04 Million | -36.93% |
| 2022-12-31 | $160.21 Million | -41.22% |
| 2021-12-31 | $272.57 Million | +273.60% |
| 2020-12-31 | $-157.01 Million | -262.83% |
| 2019-12-31 | $-43.27 Million | -122.92% |
| 2018-12-31 | $-19.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Connect Biopharma Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32649263200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.01% |
| Other Comprehensive Income | $-1.67 Million | -1.81% |
| Other Components | $439.18 Million | 476.51% |
| Total Equity | $92.17 Million | 100.00% |
Connect Biopharma Holdings Ltd Competitors by Market Cap
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
$138.09 Million |
|
Bapcor Ltd
AU:BAP
|
$138.09 Million |
|
Genesis Technology
TWO:6221
|
$138.10 Million |
|
Shree Pushkar Chemicals & Fertilisers Limited
NSE:SHREEPUSHK
|
$138.14 Million |
|
Acres Commercial Realty Corp
NYSE:ACR
|
$138.06 Million |
|
Baozun Inc
NASDAQ:BZUN
|
$138.03 Million |
|
AMPACS Corp.
TW:6743
|
$138.02 Million |
|
Wam Alternative Assets Ltd
AU:WMA
|
$137.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Connect Biopharma Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 101,043,000 to 92,166,000, a change of -8,877,000 (-8.8%).
- Net loss of 15,628,000 reduced equity.
- Other comprehensive income decreased equity by 658,000.
- Other factors increased equity by 7,409,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.63 Million | -16.96% |
| Other Comprehensive Income | $-658.00K | -0.71% |
| Other Changes | $7.41 Million | +8.04% |
| Total Change | $- | -8.79% |
Book Value vs Market Value Analysis
This analysis compares Connect Biopharma Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.78 | $2.47 | x |
| 2020-12-31 | $-2.91 | $2.47 | x |
| 2021-12-31 | $5.21 | $2.47 | x |
| 2022-12-31 | $-8.43 | $2.47 | x |
| 2023-12-31 | $1.83 | $2.47 | x |
| 2024-12-31 | $1.67 | $2.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Connect Biopharma Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -60.03%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.10x
- Recent ROE (-16.96%) is above the historical average (-25.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.69 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-104.60 Million |
| 2021 | -75.29% | 0.00% | 0.00x | 1.07x | $-232.46 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-70.04 Million |
| 2023 | -58.89% | 0.00% | 0.00x | 1.25x | $-69.61 Million |
| 2024 | -16.96% | -60.03% | 0.26x | 1.10x | $-24.84 Million |
Industry Comparison
This section compares Connect Biopharma Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Connect Biopharma Holdings Ltd (CNTB) | $55.37 Million | 0.00% | 0.22x | $138.08 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more